PMID- 35222003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220607
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Circadian Pharmacological Effects of Paeoniflorin on Mice With Urticaria-like 
      Lesions.
PG  - 639580
LID - 10.3389/fphar.2021.639580 [doi]
LID - 639580
AB  - Paeoniflorin (PF) is a monoterpene glucoside with various biological properties, 
      and it suppresses allergic and inflammatory responses in a rat model of 
      urticaria-like lesions (UL). In the present study, we treated OVA-induced mice 
      presenting UL with PF at four circadian time points (ZT22, ZT04, ZT10, and ZT16) 
      to determine the optimal administration time of PF. The pharmacological effects 
      of PF were assessed by analyzing the scratching behavior; histopathological 
      features; allergic responses such as immunoglobulin E (IgE), leukotriene B4 
      (LTB4), and histamine (HIS) release; inflammatory cell infiltration [mast cell 
      tryptase (MCT) and eosinophil protein X (EPX)]; and mRNA levels of inflammatory 
      cytokines such as interleukin (IL)-12, IL-6, interferon-gamma (IFN-gamma), and IL-4. It 
      was demonstrated that PF significantly alleviated scratching behavior and 
      histopathological features, and ZT10 dosing was the most effective time point in 
      remission of the condition among the four circadian time points. Moreover, PF 
      decreased the serum levels of IgE, LTB4, and HIS, and PF administration at ZT10 
      produced relatively superior effectiveness. PF treatment, especially dosing at 
      ZT10, significantly reduced the number of mast cells and granules and diminished 
      the infiltration of MCT and EPX in the skin tissues of mice with UL. Furthermore, 
      the oral administration of PF effectively decreased the inflammatory cytokine 
      levels of IL-12 mRNA. In conclusion, different administration times of PF 
      affected its efficacy in mice with UL. ZT10 administration demonstrated 
      relatively superior effectiveness, and it might be the optimal administration 
      time for the treatment of urticaria.
CI  - Copyright (c) 2022 Peng, Wen, Zhang, Zhang, Wei, Guo and Zeng.
FAU - Peng, Li
AU  - Peng L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Wen, Lijuan
AU  - Wen L
AD  - Clinical Skills Center, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Zhang, Jie
AU  - Zhang J
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zhang, Xiaotong
AU  - Zhang X
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Wei, Qin
AU  - Wei Q
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Guo, Jing
AU  - Guo J
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
AD  - Dermatological Department, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Zeng, Jinhao
AU  - Zeng J
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
AD  - Geriatric Department, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20220209
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
EIN - Front Pharmacol. 2022 May 19;13:918401. PMID: 35668942
PMC - PMC8863972
OTO - NOTNLM
OT  - allergic response
OT  - chronotherapeutic
OT  - inflammatory cell infiltration
OT  - inflammatory cytokine
OT  - paeoniflorin
OT  - urticaria-like lesion
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/01 06:00
MHDA- 2022/03/01 06:01
PMCR- 2022/02/09
CRDT- 2022/02/28 05:33
PHST- 2020/12/09 00:00 [received]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/02/28 05:33 [entrez]
PHST- 2022/03/01 06:00 [pubmed]
PHST- 2022/03/01 06:01 [medline]
PHST- 2022/02/09 00:00 [pmc-release]
AID - 639580 [pii]
AID - 10.3389/fphar.2021.639580 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Feb 9;12:639580. doi: 10.3389/fphar.2021.639580. 
      eCollection 2021.